With over 25 years of experience in clinical, academic, pharmaceutical medicine, and drug development, John upholds Otsuka’s mission to creating new products for better health worldwide. He is dedicated to addressing the gaps in treatment and advancing care for underserved patients. His holistic approach to overcoming challenges and finding solutions places patients at the center and inspires impactful change.

At Otsuka, John serves as Vice President of Global Clinical Development, Central Nervous System. In his role, he is responsible for the design and oversight of all clinical research programs and protocols, and he participates in due diligence of potential acquisitions, in-licensing or joint-development programs for clinical viability, and prospective commercial success.

Throughout his career, John has led, contributed to, or managed drug development programs across several psychiatric, neurological and rare diseases, including schizophrenia, major depressive disorder, anxiety disorders, bipolar disorder, Duchene muscular dystrophy, amyotrophic lateral sclerosis, myasthenia gravis, multiple sclerosis, epilepsy, Parkinson’s disease, Alzheimer’s disease, neuropathic pain and neuro injury. John also has experience in substantial regulatory engagement, including with the Food and Drug Administration, Pharmaceutical and Medical Device Agency, European Medicines Agency and Paediatric Committee. Previously, he was Senior Vice President, Global Head of CNS at Parexel International.

John received his M.D. and Ph.D. in neurobiology from Duke University in Durham, North Carolina. He completed his psychiatry residency training at the University of North Carolina, Chapel Hill, N.C., where he was also chief resident. In addition, John is a Diplomate, American Board of Psychiatry & Neurology, and a Distinguished Fellow of the American Psychiatric Association.

At Otsuka, we respect the value within every mind and I am dedicated to advancing the healthcare landscape and creating a better future for patients.